In type 1 diabetes, pramlintide did not affect hormonal, metabolic or symptomatic counter-regulatory responses to hypoglycemia compared with placebo.
In plain wordsIn type 1 diabetes, pramlintide did not change hormone, metabolic or symptom responses to low blood sugar compared with placebo.
- Peptide
- Pramlintide (Symlin)
- Outcome
- No significant changeCounter-regulatory responses to hypoglycemia
- Study
n: not reported in source
- Comparator
- Placebo
- Outcome group
- Adverse events · Metabolic and weight
- Studied dose
- 0.1-1 mg daily; 0.1-0.8 mg four times a day; 30, 100 or 300 microg three times daily · 5 or 6 days; 14 daysAs given in this study (human).
Source sentences
Pramlintide had no effect on the counter-regulatory hormonal, metabolic and symptomatic responses to hypoglycaemia.
2 context sentences(design, population, supporting numbers)
We conducted three separate randomized, placebo-controlled studies in patients with type 1 diabetes treated with adjunctive pramlintide.
These studies utilized pramlintide at high doses (either 0.1-1 mg pramlintide daily or 0.1-0.8 mg pramlintide four times a day for 5 or 6 days) as well as doses closer to those anticipated for therapeutic usage (30, 100 or 300 microg three times daily for 14 days)